Artelo Biosciences, Inc. - Common Stock (ARTL)

The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.

Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps.

As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Artelo Biosciences reported encouraging Phase 2 trial results for ART27.13 in cancer anorexia-cachexia syndrome, citing strong partner interest.

After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Artelo gets Buy rating from Boral Capital after positive updates on ART27.13, ART26.12, and preclinical success of its candidate for depression.

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.